Protara Therapeutics with ticker code (TARA) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 50 and 37 and has a mean target at 45.67. Now with the previous closing price of 24.68 this now indicates there is a potential upside of 85.0%. The 50 day MA is 22.35 and the 200 moving average now moves to 23.42. The company has a market capitalisation of $258m. You can visit the company’s website by visiting: http://www.protaratx.com
The potential market cap would be $477m based on the market concensus.
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.
